SHs need to see actual progress on these fronts as the words JC...

SHs need to see actual progress on these fronts as the words JC have proven to be hollow....

Patrys Chief Executive Officer and Managing Director, Dr. James Campbell, said: “Our collaboration with Dr Kim O’Sullivan at Monash University has continuted to identify new properties for our deoxymabs that may open up new therapeutic opportunities. The recent studies, which will be presented at the 21st International Vasculitis Workshop in Barcelona to a knowledgable and respected audience of industry peers, have indicated that deoxymabs may have a potential role in the treatment of various inflammatory diseases, and in particular certain types of vasculitis. As GMP manufacturing for PAT-DX1 remains on track to commence in the current quarter, it is exciting to identify additional therapeutic opportunities for our deoxymab platform with promising future partnering and licensing opportunities for Patrys”